Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Japan / NCT06871683
Enrolling by invitation Observational

ClotTriever® Thrombectomy System Use-Result Survey in Japan

NCT06871683 · tracked via the Priya Life Science Japan tracker
Sponsor
Inari Medical
Phase
Observational
Started
2025-02-17
Last updated
2026-09-23

Condition(s) studied

Deep Vein Thrombosis

Investigational drug(s) / intervention(s)

ClotTriever® Thrombectomy System

ClotTriever® Thrombectomy System: ClotTriever® Thrombectomy System use for treatment of patients with deep vein thrombosis with acute severe symptoms.

Study summary

The objective of this survey is to determine the safety and efficacy of the ClotTriever Thrombectomy System under daily clinical practice after marketing approval in Japan.

This device was designated as a subject of use results evaluation at the time of application for manufacturing and marketing approval.

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
This is an all-comers survey of all patients treated with ClotTriever® Thrombectomy System in Japan.

Primary outcome measure(s)

  • Rate of Major Adverse Events — Through 30 days post index procedure.
    Rate of Major Adverse Events \[All-cause mortality, Major bleeding, New symptomatic Pulmonary Embolism (PE) documented by Computed Tomography Pulmonary Angiography (CTPA), Rethrombosis of a Target Venous Segment\].
  • Technical Success — During the index procedure
    Thrombus residual volume assessed by the the treating physician using pre- and post-procedure venography to evaluate the success of thrombus removal.

Trial sites (15)

FacilityCityRegionStatus
Chiba University Hospital Chuo Chiba
Ota Memorial Hospital Ōta Gunma
St. Marianna University Hospital Kawasaki Kanagawa
National Cerebral and Cardiovascular Center Suita Osaka
Asahikawa Medical Hospital Asahikawa Japan
Asahi General Hospital Chiba Japan
Nozaki Tokushukai Hospital Daitō Japan
Shonan Kamakura Kanagawa Japan
Kyoto Katsura Hospital Kyoto Japan
Nara City Hospital Nara Japan
Osaka Police Hospital Osaka Japan
Mitsui Memorial Hospital Tokyo Japan
Keio University Tokyo Japan
Teikyo University Tokyo Japan
Mie University Tsu Japan
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06871683 on ClinicalTrials.gov ↗ ← All trials in Japan